Zymfentra U.S. Sales Surge 176% as Celltrion’s Remsima Franchise Eyes 1 Trillion Won Annual Revenue
Biopharmaceutical company Celltrion announced on Aug. 27 that combined first-half sales of its subcutaneous infliximab products—Remsima SC and...
Search results for "Remsima"
Celltrion Secures Dominant Market Share in Asia Led by Autoimmune and Oncology Biosimilars
Celltrion is consolidating its leading market position across major Asian countries with its key autoimmune and oncology therapies.
Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US
Celltrion has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 4...
Celltrion Chairman Seo Jung-jin Forgoes Summer Vacation for Global Business Tour Targeting Record Second Half
Celltrion Group Chairman Seo Jung-jin will forgo his summer vacation this August to embark on an intensive overseas...
Celltrion Files for EU Approval of Cosentyx Biosimilar CT-P55, Targeting $6.7 Billion Autoimmune Market
Celltrion announced on the 24th that it has submitted a marketing authorization application to the European Medicines...
Celltrion Secures Japanese Approval for Xolair and Eylea Biosimilars
Celltrion announced on the 27th that it has obtained marketing authorization from Japan’s Ministry of Health, Labour...
Celltrion: “Zymfentra prescriptions surging in the U.S.… growth is accelerating in earnest”
Celltrion’s subcutaneous formulation for autoimmune diseases, “Zymfentra,” which launched in the United States, has...
1